Although Polar Capital is launching its open-ended global biotech fund at a time when the sector is riding high, fund manager David Pinniger said he intends to adjust the beta of the fund's portfolio to make it attractive in any environment.

"This is a sector investors should be investing in for the long term. They need to be confident they can allocate capital to it irrespective of what the market is doing," Pinniger told